Tamoxifen: a most unlikely pioneering medicine

Baumler, E. Paul Ehrlich: Scientist for Life (Holmes & Meier, New York, 1984).

Harper, M. J. & Walpole, A. L. Contrasting endocrine activities of cis and trans isomers in a series of substituted triphenylethylenes. Nature 212, 87 (1966).

Harper, M. J. & Walpole, A. L. A new derivative of triphenylethylene: effect on implantation and mode of action in rats. J. Reprod. Fertil. 13, 101–119 (1967). First detailed report of the antifertility activity of tamoxifen in rats. The anti-oestrogen lowered circulating cholesterol but did not increase desmosterol.

Harper, M. J. & Walpole, A. L. Mode of action of I. C. I. 46,474 in preventing implantation in rats. J. Endocrinol. 37, 83–92 (1967).

Cole, M. P., Jones, C. T. & Todd, I. D. A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. Br. J. Cancer 25, 270–275 (1971). Reports the first clinical study to show tamoxifen had equivalent efficacy to historical results of standard endocrine therapy, but with fewer side effects.

Ward, H. W. Anti-oestrogen therapy for breast cancer: a trial of tamoxifen at two dose levels. Br. Med. J. 1, 13–14 (1973).

Ingle, J. N. et al. Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N. Engl. J. Med. 304, 16–21 (1981).

Beatson, G. T. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 2, 104–107 (1896).

Boyd, S. On oophorectomy in cancer of the breast. BMJ 2, 1161–1167 (1900).

Lathrop, A. E. & Loeb, L. Further investigations on the origins of tumors in mice III on the part played by internal secretions in the spontaneous development of tumors. J. Cancer Res. 1, 1–19 (1916).

Lacassagne, A. Hormonal pathogenesis of adenocarcinoma of the breast. Am. J. Cancer 27, 217–225 (1936).

Lerner, L. J. in Nonsteroidal Antioestrogens: Molecular Pharmacology and Antitumour Activity (eds. Sutherland, R. L. & Jordan, V. C.) 1–6 (Sydney Academic Press, Sydney, Australia, 1981).

Lerner, L. J., Holthaus, J. F. & Thompson, C. R. A non-steroidal estrogen antagonist 1-(p-2-diethylaminoethoxyphenyl)-1-phenyl-2-p-methoxyphenylethanol. Endocrinology 63, 295–318 (1958). The initial report of the anti-oestrogen actions of a nonsteroidal compound. The compound was, unlike tamoxifen, anti-oestrogenic in all species tested.

Duncan, G. W., Lyster, S. C., Clark, J. J. & Lednicer, D. Antifertility activities of two diphenyl-dihydroaphthalene derivatives. Proc. Soc. Exp. Biol. Med. 112, 439–442 (1963).

Legha, S. S., Slavik, M. & Carter, S. K. Nafoxidine — an antiestrogen for the treatment of breast cancer. Cancer 38, 1535–1541 (1976).

Holtkamp, D. E., Greslin, S. C., Root, C. A. & Lerner, L. J. Gonadotropin inhibiting and antifecundity effects of chloramiphene. Proc. Soc. Exp. Biol. Med. 105, 197–201 (1960).

Greenblatt, R. B., Barfield, W. E., Jungck, E. C. & Ray, A. W. Induction of ovulation with MRL-41 — Preliminary Report. JAMA 178, 101–104 (1961).

Greenblatt, R., Roy, S. & Mahesh, V. The induction of ovulation. Am. J. Obstet. Gynecol. 84, 900–912 (1962).

Whitelaw, M. J. Clomiphene citrate experience with 217 patients. Fertil. Steril. 17, 584–604 (1966).

Herbst, A. L., Griffiths, C. T. & Kistner, R. W. Clomiphene citrate (NSC-35770) in disseminated mammary carcinoma. Cancer Chemother. Rep. 43, 39–41 (1964).

Bloom, H. J. G. & Boesen, E. Antioestrogens in treatment of breast cancer: value of nafoxidine in 52 advanced cases. Br. Med. J. 2, 7–12 (1974).

William S. Merrel Company. Official Literature on New Drugs: Clomiphene citrate (Clomid). Clin. Pharmacol. Ther. 8, 891–897 (1967).

Hollander, W., Chobanian, A. V. & Wilkins, R. W. The effects of triparanol (MER-29) in subjects with and without coronary artery disease. JAMA 174, 87–94 (1960).

Laughlin, R. C. & Carey, T. F. Cataracts in patients treated with triparanol. JAMA 181, 369–370 (1962).

Avigan, J., Steinberg, D., Vroman, H. E., Thompson, M. J. & Mosettig, E. Studies of cholesterol biosynthesis. The identification of desmosterol in serum and tissues of animals and man treated with MER29. J. Biol. Chem. 235, 3123–3126 (1960).

Kraft, R. O. Triparanol in the treatment of disseminated mammary carcinoma. Cancer Chemother. Rep. 25, 113–115 (1962).

Haddow, A., Watkinson, J. M. & Paterson, E. Influence of synthetic oestrogens upon advanced malignant disease. BMJ 2, 393–398 (1944).

Walpole, A. L. & Paterson, E. Synthetic oestrogens in mammary cancer. Lancet 2, 783–789 (1949).

Bedford, G. & Richardson, D. N. Preparation and identification of cis and trans isomers of a substituted triphenylethylene. Nature 212, 733–734 (1966).

Kilbourn, B., Mais, R. H. B. & Owston, P. G. Identification of isomers of a substituted triphenylethylene: the crystal structure of 1-p-(2-dimethylaminoethoxyphenyl)1,2 cis diphenyl but1–ene hydrobromide. Chem. Commun. 1, 291 (1968).

Labhsetwar, A. P. Role of oestrogen in spontaneous ovulation demonstrated by use of an antagonist of oestrogen ICI46,474. Nature 225, 80–81 (1970).

Labhsetwar, A. P. Role of estrogen in ovulation a study using estrogen antagonist ICI46,474. Endocrinology 87, 542–551 (1970).

Labhsetwar, A. P. Effects of antioestrogen on the corpus luteum of rabbits and rats. J. Reprod. Fertil. 25, 295–297 (1971).

Labhsetwar, A. P. Role of estrogen in spontaneous ovulation: evidence for positive feedback in hamsters. Endocrinology 90, 941–946 (1972).

Jordan, V. C. The development of tamoxifen for breast cancer therapy: a tribute to the late Arthur L. Walpole. Breast Cancer Res. Treat. 11, 197–209 (1988).

Klopper, A. & Hall, M. New synthetic agent for the induction of ovulation. Preliminary trial in women. Br. Med. J. 1, 152–154 (1971).

Williamson, J. G. & Ellis, J. D. The induction of ovulation by tamoxifen. J. Obstet. Gynaecol. Br Commonwealth 80, 844–847 (1973).

El-Sheikha, Z., Klopper, A. & Beck, J. S. Treatment of menometrorrhagia with an anti-oestrogen. Clin. Endocrinology 1, 275–282 (1972).

Palopoli, F. P., Feil, V. J., Allen, R. F., Holtkamp, D. E., and Richardson Jr., A. Substituted aminoalkoxyl-triarylhaloethylenes. J. Med. Chem. 10, 84–86 (1967).

Ernst, S., Hite, G., Cantrell, J. S., Richardson Jr., A. & Benson, H. D. Stereochemistry of geometric isomers of clomiphene: a correction of structure–activity relationships. J. Pharm. Sci. 65, 148–150 (1976).

Emmens, C. W. Postcoital contraception. Br. Med. Bull. 26, 45–51 (1970).

Lunan, C. B. & Klopper, A. Antioestrogens: a review. Clin. Endocrinology 4, 551–572 (1975).

Huggins, C., Grand, L. C. & Brillantes, F. P. Mammary cancer induced by a single feeding of polynuclear hydrocarbons and their suppression. Nature 189, 204 (1961).

Jensen, E. V. & Jacobson, H. I. Basic guides to the mechanism of estrogen action. Recent Prog. Horm. Res. 18, 387–414 (1962). The pioneering studies to show the target site-specific action of radiolabelled oestradiol injected into immature rats.

Jensen, E. V., Block, G. E., Smith, S., Kyser, K. & DeSombre, E. R. Estrogen receptors and breast cancer response to adrenalectomy. Natl Cancer Inst. Monogr. 34, 55–70 (1971).

Skidmore, J. R., Walpole, A. L. & Woodburn, J. Effect of some triphenylethylenes on oestradiol binding in vitro to macromolecules from uterus and anterior pituitary. J. Endocrinol. 52, 289–298 (1972).

Jordan, V. C., Collins, M. M., Rowsby, L. & Prestwich, G. A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J. Endocrinol. 75, 305–316 (1977). The first study to show that tamoxifen, with a low affinity for the oestrogen receptor, was converted to anti-oestrogenic metabolites with high affinity. The publication of these data was delayed for more than a year to secure patent protection for the metabolites (note that tamoxifen did not have patent protection in the United States at the time.)

Allen, K. E., Clark, E. R. & Jordan, V. C. Evidence for the metabolic activation of non-steroidal antioestrogens: a study of structure-activity relationships. Br. J. Pharmacol. 71, 83–91 (1980).

Jordan, V. C. & Koerner, S. Tamoxifen (ICI 46,474) and the human carcinoma 8S oestrogen receptor. Eur. J. Cancer. 11, 205–206 (1975).

Nicholson, R. I. & Golder, M. P. The effect of synthetic anti-oestrogens on the growth and biochemistry of rat mammary tumours. Eur. J. Cancer 11, 571–579 (1975).

Jordan, V. C. & Dowse, L. J. Tamoxifen as an antitumour agent: effect on oestrogen binding. J. Endocrinol. 68, 297–303 (1976).

Jordan, V. C. Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata. Eur. J. Cancer 12, 419–424 (1976). Demonstrated that tamoxifen could not only be used to treat mammary cancer, but would also act as a preventative.

Jordan, V. C. & Jaspan, T. Tamoxifen as an antitumour agent: oestrogen binding as a predictive test for tumour response. J. Endocrinol. 68, 453–460 (1976).

Kiang, D. T. & Kennedy, B. J. Tamoxifen (antiestrogen) therapy in advanced breast cancer. Ann. Intern. Med. 87, 687–690 (1977).

NATO. Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer. Interim analysis at four years by Nolvadex Adjuvant Trial Organisation. Lancet 1, 257–261 (1983).

NATO. Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. 'Nolvadex' Adjuvant Trial Organisation. Br. J. Cancer 57, 608–611 (1988).

EBCTCG. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351, 1451–1467 (1998).

Colletta, A. A., Benson, J. R. & Baum, M. Alternative mechanisms of action of antioestrogens. Breast Cancer Res. Treat. 31, 5–9 (1994).

Lippman, M. E. & Bolan, G. Oestrogen-responsive human breast cancer in long term tissue culture. Nature 256, 592–593 (1975).

Jordan, V. C. & Allen, K. E. Evaluation of the antitumour activity of the non-steroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model. Eur. J. Cancer 16, 239–251 (1980). The first study to demonstrate, in the laboratory, that long-term anti-oestrogen therapy and a strategy of complete oestrogen blockade was going to be the best way to treat patient with receptor-positive disease.

Jordan, V. C., Dix, C. J. & Allen, K. E. in Adjuvant Therapy of Cancer (eds Salmon, S. E. & Jones, S. E.) 19–26 (Grune & Stratton, Inc., New York, 1979).

Jordan, V. C. in Reviews on Endocrine-related Cancer 49–55 (October Supplement) (1978).

Jordan, V. C., Allen, K. E. & Dix, C. J. Pharmacology of tamoxifen in laboratory animals. Cancer Treat. Rep. 64, 745–759 (1980).

Baum, M. et al. Improved survival among patients treated with adjuvant tamoxifen after mastectomy for early breast cancer. Lancet 2, 450 (1983). Clinical report demonstrating that extended adjuvant tamoxifen therapy saved lives.

Fisher, B., Dignam, J., Bryant, J. & Wolmark, N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J. Natl Cancer Inst. 93, 684–690 (2001).

Osborne, C. K., Coronado, E. B. & Robinson, J. P. Human breast cancer in the athymic nude mouse: cytostatic effects of long-term antiestrogen therapy. Eur. J. Cancer Clin. Oncol. 23, 1189–1196 (1987).

Gottardis, M. M. & Jordan, V. C. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res. 48, 5183–5187 (1988).

Jordan, V. C., Phelps, E. & Lindgren, J. U. Effects of anti-estrogens on bone in castrated and intact female rats. Breast Cancer Res. Treat. 10, 31–35 (1987). The first report that both tamoxifen and raloxifene would maintain bone density selectively, despite the fact that both prevented mammary cancer in rats.

Jordan, V. C. & Robinson, S. P. Species-specific pharmacology of antiestrogens: role of metabolism. Fed. Proc. 46, 1870–1874 (1987). Initial report that the tamoxifen–oestrogen-receptor complex would switch on or switch off oestrogen action selectively in different target tissues.

Jordan, V. C. Selective estrogen receptor modulation: a personal perspective. Cancer Res. 61, 5683–5687 (2001).

Love, R. R. et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann. Intern. Med. 115, 860–864 (1991).

Love, R. R. et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N. Engl J. Med. 326, 852–856 (1992). The first prospective randomized study to demonstrate that tamoxifen had the potential to increase bone density in postmenopausal patients. This study built on previous laboratory work.

Gottardis, M. M. & Jordan, V. C. Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res. 47, 4020–4024 (1987).

Jordan, V. C., Lababidi, M. K. & Langan-Fahey, S. Suppression of mouse mammary tumorigenesis by long-term tamoxifen therapy. J. Natl Cancer Inst. 83, 492–496 (1991).

Cuzick, J. & Baum, M. Tamoxifen and contralateral breast cancer. Lancet 2, 282 (1985).

Fisher, B. et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl Cancer Inst. 90, 1371–1388 (1998). First prospective randomized trial of high-risk pre- and postmenopausal women to demonstrate that tamoxifen reduces the risk of breast cancer. The paper confirmed all prior predictions about selective oestrogen-receptor modulation.

IBIS Investigators. First results from the International Breast Study: a randomized prevention trial. Lancet 360, 817–824 (2002).

Powles, T. J. et al. A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. Br. J. Cancer 60, 126–131 (1989).

Powles, T. et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 352, 98–101 (1998).

Gail, M. H. et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J. Natl Cancer Inst. 81, 1879–1886 (1989).

Satyaswaroop, P. G., Zaino, R. J. & Mortel, R. Estrogen-like effects of tamoxifen on human endometrial carcinoma transplanted into nude mice. Cancer Res. 44, 4006–4010 (1984).

Gottardis, M. M., Robinson, S. P., Satyaswaroop, P. G. & Jordan, V. C. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res. 48, 812–815 (1988). The first study to illustrate the target site-specificity of tamoxifen in endometrial and breast cancer. The authors suggested screening of women who were taking adjuvant tamoxifen.

Fornander, T. et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1, 117–120 (1989).

Fisher, B. et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J. Natl Cancer Inst. 86, 527–537 (1994).

Greaves, P., Goonetilleke, R., Nunn, G., Topham, J. & Orton, T. Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Res. 53, 3919–3924 (1993).

Jordan, V. C. What if tamoxifen (ICI 46,474) had been found to produce rat liver tumors in 1973? A personal perspective. Ann. Oncol. 6, 29–34 (1995).

Ettinger, B. et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282, 637–645 (1999).

Cummings, S. R. et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281, 2189–2197 (1999). Clinical proof of the concept proposed in 1990 ( Cancer Res 50, 477–489) that women taking a selective oestrogen-receptor modulator to prevent or treat osteoporosis would have a reduced incidence of breast cancer.

Buzdar, A. U., Marcus, C., Holmes, F., Hug, V. & Hortobagyi, G. Phase II evaluation of Ly156758 in metastatic breast cancer. Oncology 45, 344–345 (1988).

Jordan, V. C. Designer estrogens. Sci. Am. 279, 60–67 (1998).

Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women principal results from the women's health initiative randomized controlled trial. JAMA 288, 321–333 (2002).

Wakeling, A. E., Dukes, M. & Bowler, J. A potent specific pure antiestrogen with clinical potential. Cancer Res. 51, 3867–3873 (1991).

The ATAC Trialist Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet 359, 2131–2139 (2002).

Osborne, C. K. et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J. Clin. Oncol. 20, 3386–3395 (2002).

Howell, A. et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J. Clin. Oncol. 20, 3396–3403 (2002).

McGuire, W. L., Carbone, P. R., Sears M. F. & Escher, G. C. in Oestrogen Receptors in Human Breast Cancer (eds McGuire, W. L., Carbone, P. R. & Volmer, E. P.) 6 (Raven, New York, 1975).